SRPT
HealthcareSarepta Therapeutics, Inc. · Biotechnology · $2B
What is Sarepta Therapeutics, Inc.?
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on RNA-targeted therapeutics and gene therapies for rare diseases, particularly Duchenne muscular dystrophy.
Sarepta develops and commercializes genetic medicines targeting rare neuromuscular diseases. Revenue comes primarily from approved exon-skipping therapies for Duchenne muscular dystrophy. The company also advances a gene therapy pipeline and maintains collaboration agreements with academic and industry partners to broaden its rare-disease reach.
Incorporated in 1980 and refounded in its current form in 1997, Sarepta is headquartered in Cambridge, Massachusetts.
- EXONDYS 51 — approved exon 51 skipping therapy for Duchenne
- VYONDYS 53 — approved exon 53 skipping therapy for Duchenne
- SRP-9001 — investigational micro-dystrophin gene therapy program
- SRP-9003 — limb-girdle muscular dystrophies gene therapy program
Is SRPT a Good Stock to Buy?
UQS Score rates SRPT as Below Average overall.
The Risk and Valuation pillars both carry positive labels, suggesting the stock does not appear excessively priced relative to its profile and that certain financial risk factors are better managed than peers might expect from a rare-disease biotech.
The Quality pillar registers as Weak, which is the most significant drag on the composite score, reflecting underlying profitability challenges common to pipeline-heavy biotechs.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does SRPT pay dividends?
No — Sarepta Therapeutics, Inc. does not currently pay a dividend.
Sarepta does not pay a dividend. As a commercial-stage biopharmaceutical company still investing heavily in its pipeline, capital is directed toward research, development, and commercialization efforts rather than shareholder distributions.
When does SRPT report earnings?
Sarepta Therapeutics reports earnings on a quarterly cadence, consistent with standard US-listed equity practice.
Quarterly results typically reflect commercial revenue from approved Duchenne therapies alongside ongoing research and development expenditures. Pipeline milestones and regulatory updates often influence how the market interprets each report.
For the most recent quarter's results, visit Sarepta Therapeutics' investor relations page directly.
SRPT Price History
-72.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Sarepta Therapeutics, Inc.?
Based on Sarepta Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Sarepta Therapeutics do?
Sarepta Therapeutics develops RNA-targeted therapeutics and gene therapies for rare diseases, with a primary focus on Duchenne muscular dystrophy. It markets two approved exon-skipping therapies and maintains an active pipeline of gene therapy candidates in collaboration with academic and industry partners.
Does SRPT pay dividends?
No, SRPT does not currently pay a dividend. The company reinvests available capital into its research pipeline and commercial operations, which is typical for commercial-stage biopharmaceutical companies still scaling their approved product portfolio.
When does SRPT report earnings?
Sarepta reports on a quarterly basis, as is standard for US-listed companies. Specific dates are not covered by our data source — check Sarepta's investor relations page for the current reporting schedule.
Is SRPT a good stock to buy?
UQS Score rates SRPT as Below Average, driven largely by a Weak Quality pillar. The Risk and Valuation pillars are more favorable. Whether that profile fits your investment criteria depends on your own risk tolerance and time horizon — the full breakdown is available to Pro members.
Is SRPT overvalued?
The UQS Valuation pillar for SRPT carries a positive label, suggesting the stock does not appear significantly overpriced relative to its fundamental profile. The complete valuation metrics are available in the Pro view.
What is SRPT's market cap bracket?
Sarepta Therapeutics is classified as a mid-cap stock, placing it in a bracket that typically reflects an established commercial presence but with meaningful growth and pipeline risk still embedded in the share price.
Is SRPT a long-term quality investment?
From a long-term quality perspective, SRPT's Below Average UQS Score — anchored by a Weak Quality pillar — signals caution. The Neutral Moat and Growth pillars suggest the company has not yet built durable competitive advantages or consistent expansion trends that long-term quality investors typically seek.
What sector does SRPT belong to?
Sarepta Therapeutics operates in the Healthcare sector, specifically within rare-disease biopharmaceuticals. It focuses on genetic medicines targeting neuromuscular conditions, distinguishing it from broader drug developers.
Unlock Full SRPT Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Moat, Growth, Risk, and Valuation
- ✓Access complete financial metrics and trend data
- ✓Compare SRPT against sector peers on a standardized scoring framework
- ✓Get the full analyst-grade quality profile in one place
Pro Analysis
SRPT — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | 42.9 | 34.5 | 42.0 | 44.7 | 41.7 | 57.4 | -1.9 |
| May 7, 2026 | 44.8 | 16.3 | 42.0 | 44.7 | 67.5 | 74.3 | -0.3 |
| May 3, 2026 | 45.1 | 16.3 | 42.0 | 44.7 | 67.5 | 76.3 | -0.3 |
| Apr 26, 2026 | 45.4 | 16.3 | 42.0 | 44.7 | 67.5 | 78.2 | +0.3 |
| Apr 23, 2026 | 45.1 | 16.3 | 42.0 | 44.7 | 67.5 | 76.3 | -0.4 |
| Apr 18, 2026 | 45.5 | 16.3 | 42.0 | 44.7 | 67.5 | 79.2 | -0.1 |
| Apr 14, 2026 | 45.6 | 16.3 | 42.0 | 44.7 | 67.5 | 79.7 | -0.1 |
| Apr 12, 2026 | 45.7 | 16.3 | 42.0 | 44.7 | 67.5 | 80.4 | +0.5 |
| Apr 9, 2026 | 45.2 | 16.3 | 42.0 | 44.7 | 67.5 | 77.3 | +0.6 |
| Apr 5, 2026 | 44.6 | 16.3 | 42.0 | 44.7 | 67.5 | 72.8 | -0.2 |
SRPT — Pillar Breakdown
Quality
— 34.6/100 (25%)Sarepta Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 44.7/100 (20%)Sarepta Therapeutics, Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 41.7/100 (15%)Sarepta Therapeutics, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 57.6/100 (15%)Sarepta Therapeutics, Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 42/100 (25%)Sarepta Therapeutics, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for SRPT.
Score Composition
Financial Data
More Stock Analysis
How is the SRPT UQS Score Calculated?
The UQS (Unified Quality Score) for Sarepta Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Sarepta Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Sarepta Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.